Welcome to the first issue of Biopharma Insights, a new research series from Serra Wealth dedicated to one of the most compelling corners of today's market: biotechnology and pharmaceuticals. In upcoming issues, we’ll explore the innovations driving the sector and what they mean for investors, with advisory clients getting access to educational case studies showing how these themes translate into specific trade ideas.
Why launch this series now? In an era of stretched AI valuations, where a handful of mega-cap tech companies hold most of the market's capital and growth, a liquid, fast-growing and largely uncorrelated sector can be a valuable diversifier for smart investors. Biopharma stands out as a compelling opportunity: after four difficult years, it entered a new bull cycle.
The long winter is over
From its February 2021 peak, the biotech sector fell more than 60% into April 2025, a stretch industry veterans dubbed the "biotech winter." That winter has ended. The benchmark SPDR S&P Biotech ETF (XBI) returned nearly 36% in 2025 and has climbed a further \~39% year-to-date in 2026 — roughly 91% over the trailing twelve months — closing at a fresh high on August 19. Pharma and biotech have outperformed the broader market since mid-2025 — offering a growth driver with relatively low correlation to the mega-cap AI trade, and a useful diversifier. The capital markets have reopened too: after a historic IPO drought in 2025, roughly two dozen biotechs have gone public in 2026, already about double last year's tally, led by Parabilis Medicines' $670 million IPO in June — the largest venture-backed biotech IPO on record.
Big Pharma is buying — aggressively
Biopharma companies spent $134 billion on M&A in the first half of 2026, with 33 deals worth a billion dollars or more apiece — already past the roughly $112 billion spent in all of 2025. The buying hasn't let up since. Industry trackers now put 2026 dealmaking near $190 billion, on track for the sector's biggest year since before the pandemic, and acquirers are paying up to win assets. When Vertex agreed to buy Crinetics Pharmaceuticals for about $10 billion in July, it offered roughly double what the stock had traded for the day before.
The M&A driver is durable: Big Pharma companies face looming patent cliffs on blockbuster drugs and urgently need to refill their pipelines, which makes them motivated buyers. Eli Lilly has spent close to $28 billion across eleven deals this year, and shows no sign of stopping. For investors, this creates a powerful setup: a deep-pocketed buyer base with an increasingly urgent need to acquire the next generation of assets.
AI: A tailwind, not the thesis
AI is starting to reshape the earliest, most tractable parts of drug development: designing and screening molecules faster than ever, with early PitchBook data showing AI-native biotechs posting higher Phase I success rates than the industry average. As companies continue to integrate AI into the development pipeline, analysts project that it could nearly double the success rate of investigational new drug applications while cutting timelines and costs. In other words, biopharma offers investors exposure to AI's upside without paying the valuations now attached to the mega-cap tech names driving the AI trade.
A catalyst-rich calendar
Biopharma is uniquely suited to options strategies because its returns cluster around identifiable, anticipated events: FDA approval decisions, clinical trial readouts, and drug launches. These catalysts fall in windows we can anticipate — and 2026 offers an unusually dense slate of them.
If you'd like to discuss whether (and how much) biopharma exposure fits your portfolio and risk tolerance, your Serra Wealth advisor is the right first call. Welcome aboard; it's a fascinating time to be looking at this sector.
— Ife Desamours, Serra Wealth Biopharma Team
Important disclosures
This newsletter is a marketing communication provided for information purposes only. It does not constitute investment advice, a personal recommendation, or an offer or solicitation to buy or sell any financial instrument. References to specific securities are illustrative only and are not recommendations; examples cited are not representative of all names followed, and other securities monitored did not perform comparably. Options are complex instruments and carry a high risk of rapid loss; certain strategies can result in losses exceeding the initial amount invested. Biotechnology securities are highly volatile and exposed to binary clinical and regulatory events. Simulated past performance and actual past performance are not reliable indicators of future performance. Investors should consider their objectives, financial situation and risk tolerance, and consult their Serra Wealth advisor, before acting on any information herein. Capital is at risk.